Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.75 |
| ▸ | AURKB | Q96GD4 | 11/20 | 0.75 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771697 | 1.00 | KDR (0.75) | KDRAURKBLRRK2PTK2PTK2B | |
| SCHEMBL3783510 | 0.88 | KDR (0.79) | KDRAURKBJAK2JAK1JAK3 | |
| SCHEMBL3778501 | 0.88 | KDR (0.79) | KDRAURKBJAK2JAK1JAK3 | |
| SCHEMBL3767811 | 0.87 | KDR (0.69) | KDRAURKBLRRK2JAK2JAK1 | |
| SCHEMBL1702994 | 0.87 | KDR (0.69) | KDRAURKBLRRK2JAK2JAK1 | |
| SCHEMBL3773560 | 0.86 | AURKB (1.00) | KDRAURKBJAK2JAK1JAK3 | |
| SCHEMBL1703631 | 0.86 | AURKB (1.00) | KDRAURKBJAK2JAK1JAK3 | |
| SCHEMBL3778135 | 0.84 | AURKB (1.00) | KDRAURKBJAK2JAK1JAK3 | |
| SCHEMBL1703907 | 0.84 | AURKB (1.00) | KDRAURKBJAK2JAK1JAK3 | |
| SCHEMBL5577046 | 0.82 | PTK2 (0.57) | KDRAURKBPTK2PTK2BJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | claimed |
| EP-2440548-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | Abbott Laboratories (US) | 2012-04-18 | — | — | EP | claimed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | claimed |
| WO-2010144468-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | claimed |
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2440548-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | Abbott Laboratories (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144468-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | KDR 38/4885AURKB 3/4885LRRK2 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.